Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Berntorp

Showing results (41-50 of 250) with videos related to

Pageof 25
Sort By:
Scandinavian Journal of Haematology|March 1, 1985
High expression of lymphocyte surface immunoglobulin in chronic lymphocytic leukaemia may be a bad prognostic signE Berntorp, O Zettervall
Clinical Pharmacokinetics|December 12, 2001
Pharmacokinetics of coagulation factors: clinical relevance for patients with haemophiliaS Björkman, E Berntorp
Haemophilia : the Official Journal of the World Federation of Hemophilia|January 5, 1999
Continuous infusion of factor IX concentrate to induce immune tolerance in two patients with haemophilia BL Tengborn, E Berntorp
Haemophilia : the Official Journal of the World Federation of Hemophilia|January 20, 2009
Treatment and prevention of acute bleedings in von Willebrand disease--efficacy and safety of Wilate, a new generation von Willebrand factor/factor VIII concentrateE Berntorp, J Windyga,
Vox Sanguinis|October 26, 1999
Malmö International Brother Study (MIBS): an international survey of brother pairs with haemophiliaJ Astermark, E Berntorp
Journal of Internal Medicine|August 30, 2014
Inhibitors in haemophilia: what have we learned from registries? A systematic reviewM Osooli, E Berntorp
Vox Sanguinis|January 1, 1989
Use of a high-purity factor VIII concentrate (Hemate P) in von Willebrand's diseaseE Berntorp, I M Nilsson
Progress in Clinical and Biological Research|January 1, 1990
Induction of immune tolerance in hemophiliacs with inhibitors by combined treatment with i.v. IgG, cyclophosphamide and factor VIII or IXI M Nilsson, E Berntorp
Vox Sanguinis|January 1, 1996
Immune tolerance and the immune modulation protocolE Berntorp, I M Nilsson
European Journal of Haematology|March 1, 1988
Biochemical and in vivo properties of commercial virus-inactivated factor VIII concentratesE Berntorp, I M Nilsson
Pageof 25

Showing results (41-50 of 250) with videos related to

Sort By:
Pageof 25
Scandinavian Journal of Haematology|March 1, 1985
High expression of lymphocyte surface immunoglobulin in chronic lymphocytic leukaemia may be a bad prognostic signE Berntorp, O Zettervall
Clinical Pharmacokinetics|December 12, 2001
Pharmacokinetics of coagulation factors: clinical relevance for patients with haemophiliaS Björkman, E Berntorp
Haemophilia : the Official Journal of the World Federation of Hemophilia|January 5, 1999
Continuous infusion of factor IX concentrate to induce immune tolerance in two patients with haemophilia BL Tengborn, E Berntorp
Haemophilia : the Official Journal of the World Federation of Hemophilia|January 20, 2009
Treatment and prevention of acute bleedings in von Willebrand disease--efficacy and safety of Wilate, a new generation von Willebrand factor/factor VIII concentrateE Berntorp, J Windyga,
Vox Sanguinis|October 26, 1999
Malmö International Brother Study (MIBS): an international survey of brother pairs with haemophiliaJ Astermark, E Berntorp
Journal of Internal Medicine|August 30, 2014
Inhibitors in haemophilia: what have we learned from registries? A systematic reviewM Osooli, E Berntorp
Vox Sanguinis|January 1, 1989
Use of a high-purity factor VIII concentrate (Hemate P) in von Willebrand's diseaseE Berntorp, I M Nilsson
Progress in Clinical and Biological Research|January 1, 1990
Induction of immune tolerance in hemophiliacs with inhibitors by combined treatment with i.v. IgG, cyclophosphamide and factor VIII or IXI M Nilsson, E Berntorp
Vox Sanguinis|January 1, 1996
Immune tolerance and the immune modulation protocolE Berntorp, I M Nilsson
European Journal of Haematology|March 1, 1988
Biochemical and in vivo properties of commercial virus-inactivated factor VIII concentratesE Berntorp, I M Nilsson
Pageof 25